Pages that link to "Q41347185"
Jump to navigation
Jump to search
The following pages link to Chronic nicotine treatment counteracts the disappearance of tyrosine-hydroxylase-immunoreactive nerve cell bodies, dendrites and terminals in the mesostriatal dopamine system of the male rat after partial hemitransection (Q41347185):
Displaying 46 items.
- Multiple roles for nicotine in Parkinson's disease (Q22252514) (← links)
- Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice (Q28363006) (← links)
- Nicotinic receptors and Parkinson's disease (Q28377091) (← links)
- Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra (Q31813959) (← links)
- Developmental cholinotoxicants: nicotine and chlorpyrifos (Q33608802) (← links)
- Central nicotinic receptors, neurotrophic factors and neuroprotection (Q34002742) (← links)
- Nicotine and nicotinic receptors; relevance to Parkinson's disease (Q34995021) (← links)
- Chronic nicotine treatment increases nAChRs and microglial expression in monkey substantia nigra after nigrostriatal damage (Q35098275) (← links)
- Neuroprotective strategies in Parkinson's disease : an update on progress (Q35182054) (← links)
- Nicotine and Parkinson's disease: implications for therapy (Q35601652) (← links)
- Ciliary neurotrophic factor prevents degeneration of adult rat substantia nigra dopaminergic neurons in vivo (Q36406386) (← links)
- Nicotinic receptor agonists as neuroprotective/neurotrophic drugs. Progress in molecular mechanisms (Q36564840) (← links)
- Nicotinic receptors as CNS targets for Parkinson's disease (Q36882136) (← links)
- Effects of nicotine during pregnancy: human and experimental evidence (Q37131130) (← links)
- Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys (Q37180827) (← links)
- Alpha7 nicotinic receptors as therapeutic targets for Parkinson's disease (Q38532889) (← links)
- Cigarette smoke, nicotine and cotinine protect against 6-hydroxydopamine-induced toxicity in SH-SY5Y cells (Q39999584) (← links)
- The nicotinic acetylcholine receptor agonist ( /-)-epibatidine increases FGF-2 mRNA and protein levels in the rat brain (Q40905127) (← links)
- Does nicotine have beneficial effects in the treatment of certain diseases? (Q40923282) (← links)
- Nicotine: abused substance and therapeutic agent (Q41741650) (← links)
- Chronic nicotine treatment increases dopamine levels and reduces dopamine utilization in substantia nigra and in surviving forebrain dopamine nerve terminal systems after a partial di-mesencephalic hemitransection (Q41826903) (← links)
- Desensitization of the nicotine-induced mesolimbic dopamine responses during constant infusion with nicotine (Q42369697) (← links)
- Presynaptic involvement in the nicotine prevention of the dopamine loss provoked by 6-OHDA administration in the substantia nigra (Q42443783) (← links)
- Differential alterations in nicotinic receptor alpha6 and beta3 subunit messenger RNAs in monkey substantia nigra after nigrostriatal degeneration (Q42493545) (← links)
- Vulnerability of 125I-alpha-conotoxin MII binding sites to nigrostriatal damage in monkey. (Q42507674) (← links)
- Acute intermittent nicotine treatment produces regional increases of basic fibroblast growth factor messenger RNA and protein in the tel- and diencephalon of the rat. (Q42673244) (← links)
- Nicotine administration reduces striatal MPP levels in mice (Q43770932) (← links)
- Stimulation of non-alpha7 nicotinic receptors partially protects dopaminergic neurons from 1-methyl-4-phenylpyridinium-induced toxicity in culture (Q43860478) (← links)
- The neuroprotective effect of nicotine in Parkinson's disease models is associated with inhibiting PARP-1 and caspase-3 cleavage (Q47146624) (← links)
- Chronic continuous infusion of nicotine increases the disappearance of choline acetyltransferase immunoreactivity in the cholinergic cell bodies of the medial septal nucleus following a partial unilateral transection of the fimbria fornix (Q48166132) (← links)
- Studies on the influence of nicotine infusions on mesolimbic dopamine and locomotor responses to nicotine (Q48184972) (← links)
- Persistent c-fos induction by nicotine in developing rat brain regions: interaction with hypoxia (Q48304624) (← links)
- Alzheimer's drug design based upon an invertebrate toxin (anabaseine) which is a potent nicotinic receptor agonist (Q48369775) (← links)
- The vigilance-promoting drug modafinil counteracts the reduction of tyrosine hydroxylase immunoreactivity and of dopamine stores in nigrostriatal dopamine neurons in the male rat after a partial transection of the dopamine pathway (Q48386791) (← links)
- Histological and Behavioral Protection by (−)-Nicotine against Quinolinic Acid-Induced Neurodegeneration in the Hippocampus (Q48445475) (← links)
- Differential effects of acute and chronic nicotine treatment on MPTP-(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced degeneration of nigrostriatal dopamine neurons in the black mouse (Q48519851) (← links)
- Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis (Q48863958) (← links)
- Hypertrophy of dopamine neurons in the primate following ventromedial mesencephalic tegmentum lesion (Q48810226) (← links)
- Intraventricular infusion of epidermal growth factor restores dopaminergic pathway in hemiparkinsonian rats (Q48824397) (← links)
- Nicotine withdrawal: a behavioral assessment using schedule controlled responding, locomotor activity, and sensorimotor reactivity. (Q52228758) (← links)
- Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease and in relation to neuroleptic medication. (Q53341479) (← links)
- Studies of protective actions of nicotine on neuronal and vascular functions in the brain of rats: comparison between sympathetic noradrenergic and mesostriatal dopaminergic fiber systems, and the effect of a dopamine agonist (Q69376642) (← links)
- Protective effects of chronic nicotine treatment on lesioned nigrostriatal dopamine neurons in the male rat (Q69389544) (← links)
- The short-term effect of nicotine chewing gum in patients with Parkinson's disease (Q72246043) (← links)
- Perinatal asphyxia-induced changes in rat brain tyrosine hydroxylase-immunoreactive cell body number: effects of nicotine treatment (Q73274856) (← links)
- Epidemiological studies: risk factors session IV summary and research needs (Q77599277) (← links)